Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>KC02

KC02

Katalog-Nr.GC13023

Structural analog and inactive form of KC01

Products are for research use only. Not for human use. We do not sell to patients.

KC02 Chemische Struktur

Cas No.: 1646795-60-9

Größe Preis Lagerbestand
5mg
892,00 $
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

KC02 is a structural analog of KC01 and inactive form of KC01.
The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assys, KC02 inhibited ABHD16A (human and mouse) with IC50 value of >10μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC50 value of > 10μM, while KC01 is in range of nM.
Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1μM, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12−/− macrophages with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h).
In COLO205 cells, 1μM KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.
KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12+/+ and Abhd12−/− mice.
Reference:
1.Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015 Feb;11(2):164-71.

Bewertungen

Review for KC02

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for KC02

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.